Hippocampus and

The effects of VIP and PACAP are mediated by three GPCR subtypes, VIP, VIP2, and PACAP receptor, coupled to the activation of adenjiate cyclase (54). The VIP subtype is localized ia the lung, Hver, and iatestiae, and the cortex, hippocampus, and olfactory bulb ia the CNS. The VIP2 receptor is most abundant ia the CNS, ia particular ia the thalamus, hippocampus, hypothalamus, and suprachiasmatic nucleus. PACAP receptors have a wide distribution ia the CNS with highest levels ia the olfactory bulb, the dentate gyms, and the cerebellum (84). The receptor is also present ia the pituitary. The VIP and PACAP receptors have been cloned. 

Similar to C1C-5, C1C-3 is present in endosomes. It is also found in synaptic vesicles. In both instances, and similar to C1C-5, it is necessary for the efficient intravesicular acidification. The acidification of synaptic vesicles is particularly important as their uptake of neurotransmitters depends on the electrochemical proton gradient. Surprisingly, the disruption of C1C-3 in mice resulted in a drastic degeneration of the hippocampus and the retina. Much less is known about C1C-4, which, however, also appears to be present in endosomal compartments. 

Dronabinol (tetrahydrocannabinol), the active principle from cannabis and synthetic cannabinoids, nabilone and levonantradol are effective in treating nausea and vomiting in cancer chemotherapy. The mode of action is unclear but appears to involve cannabinoid CBi receptors. Cannabinoids have been shown to reduce acetylcholine release in the cortex and hippocampus, and have been suggested to inhibit medullary activity by a cortical action. Inhibition of prostaglandin synthesis and release of endorphins may also be involved in the antiemetic effect. A review of trials of dronabinol, nabilone or levonantradol concluded that while the cannabinoids were superior to placebo or dopamine receptor antagonists in controlling emesis... 

Ryabinin AE, Criado JR, Henriksen SJ, et al Differential sensitivity of c-Fos expression in hippocampus and other brain regions to moderate and low doses of alcohol. Mol Psychiatry 2 32 3, 1997... 

Recently, there has been a growth of interest in the development of in vitro methods for measuring toxic effects of chemicals on the central nervous system. One approach has been to conduct electrophysiological measurements on slices of the hippocampus and other brain tissues (Noraberg 2004, Kohling et al. 2005). An example of this approach is the extracellular recording of evoked potentials from neocortical slices of rodents and humans (Kohling et al. 2005). This method, which employs a three-dimensional microelectrode array, can demonstrate a loss of evoked potential after treatment of brain tissue with the neurotoxin trimethyltin. Apart from the potential of in vitro methods such as this as biomarkers, there is considerable interest in the use of them as alternative methods in the risk assessment of chemicals, a point that will be returned to in Section 16.8. 

Modern sensitive chromatographic and voltammetric techniques now make it possible to estimate the release of unlabelled endogenous transmitter from slices of brain tissue (commonly the hippocampus and striatum) or spinal cord (Fig. 4.4). However, whatever analytical method is used, the thickness of the slice is paramount. It is important to maintain the balance between preserving the integrity of the tissue (the thicker the slice, the better) against maintaining tissue viability by perfusion with oxygenated aCSF (the thinner the slice, the better). 

D5 Highest concentration in hippocampus and hypothalamus but much lower expression overall. Also linked to stimulation of adenylate cyclase but higher submicromolar affinity for DA (ifi 200nM). Also found in rat striatum and nucleus accumbens. 

Many brain areas are innervated by neurons projecting from both the locus coeruleus and the lateral tegmental system but there are exceptions (Fig. 8.3). The frontal cortex, hippocampus and olfactory bulb seem to be innervated entirely by neurons with cell bodies in the locus coeruleus whereas most hypothalamic nuclei are innervated almost exclusively by neurons projecting from the lateral tegmental system. The paraventricular nucleus (and possibly the suprachiasmatic nucleus, also) is an exception and receives an innervation from both systems. 

This peptide itself has no selectivity for the two CCK receptors, CCK-A and B, which have so far been established to stimulate IP3/DAG while, like substance P, can close potassium channels to increase neuronal activity. The CCK-B receptor is thought to predominate in the CNS but species differences may make this interpretation difficult. It has a wide distribution in the CNS but is also found in the gut whereas the CCK-A receptor is more restricted but is found in the hypothalamus, hippocampus and in the brainstem. There are high levels of the natural peptide, CCK-8 in cortex, hippocampus, hypothalamus, ventral tegmentum, substantia nigra, brainstem and spinal cord. CCK is one of the most abundant peptides in the brain and CCK co-exists with dopamine, substance P, 5-HT and vasopressin. Interestingly, in the dopamine areas, CCK co-exists in the mesolimbic pathways but in the nigrostriatal projections, the peptide and... 

Autoradiography and receptor mRNA studies have shown Hi receptors to be located in most of the brain areas innervated by the ascending histaminergic axons, e.g. cerebral cortex, hippocampus, limbic areas and hypothalamus. Their presence in the cerebellum is not accompanied by appropriate histaminergic innervation. Very few are found in the striatum but this region does show a high density of H2 receptors. H2 receptors are also found with Hi in the cortex, hippocampus and limbic areas, but not in the hypothalamus. Although basically presynaptic the H3 receptor is also found postsynaptically in the striatum and cerebral cortex (Pollard et al. 1993). 

While there are some reports of increased NMDA and non-NMDA receptor number in various cortical regions of schizophrenics including the prefrontal cortex, there are also indications of impaired glutamate innervation, such as reduction in its neuronal uptake sites (Ishimaru, Kurumaji and Torn 1994). Also it has been found that levels of the mRNA for the NRI subunit of the NMDA receptor in the hippocampus and its D-aspartate binding sites in the temporal cortex are both reduced more on the left than right side in schizophrenic brain. This is another indication of greater malfunction on the left side of the brain and the possibility that some schizophrenic symptoms arise from an imbalance between cross-cortical activity. 

These are intraneuronal cytoplasmic lesions found predominantly in large pyramidal cells, again, mostly within the hippocampus and frontal temperal cortex, and while they... 

Even if there is a link between the presence of tangles and plaques and the emergence of AzD, it is by no means certain how those markers could be responsible for all the symptoms. They do not seem to be sufficiently numerous or widely spread to disrupt brain function to the extent that eventually occurs in AzD, although their preferential location in the hippocampus and the known association of that area with memory processing could explain the loss of that faculty. 

Low concentrations of solubilised jS-albumin inhibit ACh release in slices from rat hippocampus and cortex areas which show degeneration in AzD, but not in slices from the striatum which is unaffected. While not totally specific to ACh, since some inhibition of NA and DA and potentiation of glutamate release have been reported, this effect is achieved at concentrations of A/i below those generally neurotoxic. Since jS-amyloid can inhibit choline uptake it is also possible (see Auld, Kar and Quiron 1998) that in order to obtain sufficient choline for ACh synthesis and the continued function of cholinergic neurons, a breakdown of membrane phosphatidyl choline is required leading to cell death (so-called autocannibalism), /i-amyloid can also reduce the secondary effects of Mi receptor activation such as GTPase activity... 

Among a number of peptides studied it is only the reduction of somatostatin in the temporal, parietal and frontal cortices that correlates with the severity of dementia in AzD, although corticotrophin-releasing factor is lower. Reductions in somatostatin do not generally parallel those of ChAT, its concentration being almost normal in the hippocampus and nucleus basalis, where ChAT levels are lowest and there is no evidence that it is localised in cholinergic neurons. 

Competition binding studies showing that when using compounds like jS-CCE (ethyl- S-carboline-3-carboxylate), which bind to the benzodiazepine receptor, the displacement curve for [ H]flunitrazepam was shallow in the hippocampus and... 

---